Mr. Ken d'Entremont reports

MEDEXUS SCHEDULES SECOND FISCAL QUARTER 2024 CONFERENCE CALL

Medexus Pharmaceuticals Inc. plans to host a conference call at 8 a.m. ET on Thursday, Nov. 9, 2023, to discuss Medexus's results for its second fiscal quarter ended Sept. 30, 2023. Medexus expects to file its financial statements and MD&A (management's discussion and analysis) after markets close on Nov. 8, 2023.

To participate in the call, please dial the following numbers:

• 888-506-0062 (toll-free) for Canadian and United States callers;
• 1-973-528-0011 for international callers;
• Access code: 369779.

A live webcast of the call will be available on the investors section of Medexus's corporate website.

A replay of the call will be available approximately one hour following the end of the call through Thursday, Nov. 16, 2023. To access the replay, please dial the following numbers:

• 877-481-4010 for Canadian and U.S. callers;
• 1-919-882-2331 for international callers;
• Conference ID: 49370.

A replay of the webcast will be available on the investors section of Medexus's corporate website until Saturday, Nov. 9, 2024.

About Medexus Pharmaceuticals Inc.

Medexus is a leading specialty pharmaceutical company with a strong North American commercial platform and a growing portfolio of innovative and rare disease treatment solutions. Medexus's current focus is on the therapeutic areas of oncology, hematology, rheumatology, auto-immune diseases, allergy and dermatology.

We seek Safe Harbor.